Research Topics
| Peter ThallSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carciNizar M Tannir
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 107:2254-61. 2006..In a randomized Phase II trial, the authors tested the hypothesis that twice-daily low-dose IFN is more effective than daily intermediate-dose IFN in patients with metastatic renal cell cancer (MRCC)...
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agentsNizar M Tannir
Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 180:867-72; discussion 872. 2008..We assessed the clinical activity and safety of gemcitabine plus capecitabine in patients with metastatic renal cell cancer previously treated with immunotherapy...
Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomesPeter F Thall
Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
J Biopharm Stat 22:785-801. 2012..The method is illustrated by a Phase I/II trial of radiation therapy for children with brainstem gliomas...- Accrual strategies for phase I trials with delayed patient outcomeP F Thall
Department of Biomathematics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
Stat Med 18:1155-69. 1999..Based on our results, we provide practical guidelines for deciding among these approaches and strategies in a given clinical setting... - Practical model-based dose-finding in phase I clinical trials: methods based on toxicityP F Thall
Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Int J Gynecol Cancer 13:251-61. 2003..The comparisons show that the Bayesian methods are much more reliable than the conventional algorithm for selecting an MTD, and that they have a low risk of treating patients at unacceptably toxic doses... - A review of phase 2-3 clinical trial designsPeter F Thall
Department of Biostatistics, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Lifetime Data Anal 14:37-53. 2008..A general conclusion is that, in many circumstances, a properly designed phase 2-3 trial utilizes resources much more efficiently and provides much more reliable inferences than conventional methods... - Dose-finding with two agents in Phase I oncology trialsPeter F Thall
Department of Biostatistics, Box 447, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
Biometrics 59:487-96. 2003..A method for eliciting the single-agent parameter priors is described. The design is applied to a trial of gemcitabine and cyclophosphamide, and a simulation study is presented... - Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoringPeter F Thall
Department of Biostatistics, University of Texas, Houston, TX, USA
Stat Med 26:4687-702. 2007..Advantages and disadvantages of this design compared to standard methods are discussed... - Practical Bayesian adaptive randomisation in clinical trialsPeter F Thall
Department of Biostatistics, Box 447, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Eur J Cancer 43:859-66. 2007..The method will first be illustrated by a simple hypothetical example, then by a recent trial in which patients with unresectable soft tissue sarcoma were adaptively randomised between two chemotherapy regimens... - Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and ceP F Thall
Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Bone Marrow Transplant 33:1191-9. 2004..For these patients, the posterior probability that i.v.BuCy2 was superior to alternative conditioning regimens ranges from 0.54 to 0.99, depending on prognosis and the magnitude of the assumed center effect... - Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerationsPeter F Thall
Department of Biostatistics and Applied Mathematics, The University of Texas, MD Anderson Cancer Center, Houston, USA
J Biopharm Stat 16:623-38. 2006..To illustrate how the method may work in practice, we present a cohort-by-cohort example of a particular trial. We close with a discussion of some practical issues that may arise during implementation... - Some ethical issues in phase II trials in acute leukemiaPeter F Thall
Department of Biostatistics and Applied Mathematics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
Clin Adv Hematol Oncol 3:943-8. 2005..The general conclusions are that statistical designs have both scientific and ethical implications, and that science, statistics, and ethics cannot be treated as separate issues... - Dose-finding based on efficacy-toxicity trade-offsPeter F Thall
Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Biometrics 60:684-93. 2004..Computer simulations show that, under a wide rage of dose-outcome scenarios, the new method has high probabilities of making correct decisions and treats most patients at doses with desirable efficacy-toxicity trade-offs... - A geometric approach to comparing treatments for rapidly fatal diseasesPeter F Thall
Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Biometrics 62:193-201. 2006..Posterior probabilities of this set are used to construct rules for the treatment comparison and safety monitoring. The method is illustrated by a randomized trial comparing two cord blood transplantation methods... - Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatmentsPeter F Thall
Department of Biostatistics, Box 447, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, U S A
Stat Med 24:1947-64. 2005..The adaptive randomization procedure generalizes the method proposed by Thompson (1933) for two binomial distributions with beta priors. A simulation study of the design in the context of the sarcoma trial is presented... - Patient-specific dose finding based on bivariate outcomes and covariatesPeter F Thall
Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Biometrics 64:1126-36. 2008..The method is illustrated by a dose-finding trial in acute leukemia, including a simulation study... - Bayesian designs to account for patient heterogeneity in phase II clinical trialsPeter F Thall
Department of Biostatistics, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
Curr Opin Oncol 20:407-11. 2008..The second design uses a hierarchical model for settings where, a priori, the experimental treatment effects in the subgroups are assumed to be exchangeable... - Monitoring event times in early phase clinical trials: some practical issuesPeter F Thall
Department of Biostatistics and Applied Mathematics, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Trials 2:467-78. 2005..In such settings, it often is more natural to construct early stopping rules based on time-to-event variables. This type of design may involve a variety of complications, however... - Optimal two-stage designs for clinical trials based on safety and efficacyP F Thall
Department of Biostatistics, Box 447, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Stat Med 20:1023-32. 2001..A more general group-sequential version of the design also is described, an illustration is provided, and application to the special case of single-arm phase II trials is discussed... - Dose-finding based on feasibility and toxicity in T-cell infusion trialsP F Thall
Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Biometrics 57:914-21. 2001..The method is illustrated by application to a dendritic cell activated lymphocyte infusion trial in the treatment of acute leukemia. A simulation study indicates that the proposed methodology is both safe and reliable... - Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapiesPeter F Thall
Department of Biostatistics, M D Anderson Cancer Center, Houston, TX, U S A
Stat Med 30:1777-94. 2011..The methods are illustrated by a data set arising from 224 pediatric brain tumor patients treated with over 27 different chemo combinations involving seven chemo agents... - Optimizing the concentration and bolus of a drug delivered by continuous infusionPeter F Thall
Department of Biostatistics, M D Anderson Cancer Center, Houston, Texas 77030, USA
Biometrics 67:1638-46. 2011..The methodology is illustrated by a trial in which tissue plasminogen activator is infused intraarterially as rapid treatment for acute ischemic stroke... - Ethical issues in oncology biostatisticsPeter F Thall
Department of Biostatistics, Box 447, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Stat Methods Med Res 11:429-48. 2002..I describe particular experiences and the ethical issues involved. Topics include medical decision making, benefit-harm trade-offs, safety monitoring, adaptive randomization, informed consent, and publication bias... - Adaptive decision making in a lymphocyte infusion trialPeter F Thall
Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biometrics 58:560-8. 2002..A simulation study shows that the design reliably selects the best infusion time while randomizing greater proportions of patients to superior infusion times... - Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesPeter F Thall
Department of Biostatistics, Box 447, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Stat Med 22:763-80. 2003..The applications illustrate how the hierarchical Bayesian model borrows strength across subtypes... - Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostateChristos N Papandreou
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:3072-80. 2002..To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa... - Determining a maximum-tolerated schedule of a cytotoxic agentThomas M Braun
Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109, USA
Biometrics 61:335-43. 2005.... - Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimensPeter F Thall
Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Natl Cancer Inst 99:1613-22. 2007..With the goal of efficiently selecting promising regimens for more advanced trials, we conducted a randomized selection trial of four regimens to identify promising treatments for androgen-independent prostate cancer... - A pilot study of thalidomide in patients with progressive metastatic renal cell carcinomaDanai D Daliani
Department of Genitourinary Medical Oncology, M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 95:758-65. 2002..Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (VEGF)-induced angiogenesis... - Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan
Genitourinary Medical Oncology Department, University of Texas M D Anderson Cancer Center, Houston, TX 77040 4009, USA
J Clin Oncol 21:878-83. 2003..We used a randomized phase II design to evaluate and compare two such regimens. Patients were accrued primarily in the community setting... - Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapiesShifeng Mao
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 3721, USA
Prostate 67:1677-85. 2007.... - Seamlessly expanding a randomized phase II trial to phase IIILurdes Y T Inoue
Department of Biostatistics, University of Washington, Box 357232, Seattle, Washington 98195, USA
Biometrics 58:823-31. 2002.... - Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 97:561-7. 2003.... - Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemiaPaul M Armistead
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston Texas, USA
Biol Blood Marrow Transplant 15:1431-8. 2009..Our data suggest that HSCT is preferable to chemotherapy alone in these patients with poor prognoses, with particular benefits noted in patients under age 50 years... - Continuous Bayesian adaptive randomization based on event times with covariatesYing Kuen Cheung
Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
Stat Med 25:55-70. 2006..We illustrate these methods by application to a phase II selection trial in acute leukaemia. A simulation study in the context of this trial is presented... - Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remissionStefan Faderl
Department of Leukaemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Br J Haematol 117:869-74. 2002..We conclude that a quicker TPR predicts longer DFS and OS in patients with ALL. As platelet counts are obtained almost daily in patients undergoing chemotherapy, TPR can readily be utilized to assess the prognosis of these patients... - Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomesJanice N Cormier
Sarcoma Center and Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA
J Clin Oncol 22:4567-74. 2004..These results suggest that caution should be used in the interpretation of randomized clinical trials of adjuvant chemotherapy that seem to demonstrate clinical benefits with relatively short-term follow-up... - Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer CenterJohannes E Wolff
Department of Pediatrics, M D Anderson Cancer Center, Houston, TX, USA
Anticancer Res 31:2265-9. 2011..The biology of diffuse intrinsic pontine glioma remains poorly understood and the dismal prognosis has not changed despite various attempts to add chemotherapy to standard radiation... - Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AMLElihu H Estey
Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
Blood 102:3097-9. 2003..0. Thus, our data do not support use of PBBs in defining CR in newly diagnosed AML... - Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:5816-24. 2007.... - Accounting for patient heterogeneity in phase II clinical trialsJ Kyle Wathen
Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Box 447, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Stat Med 27:2802-15. 2008..A simulation study is presented and the method is illustrated by a chemotherapy trial in acute leukemia... - Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancerPaul Mathew
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
J Urol 181:81-7; discussion 87. 2009..Men with high risk localized prostate cancer were treated with platelet derived growth factor receptor inhibitor therapy, docetaxel and hormone ablation in the preoperative setting, and clinicopathological outcomes were evaluated... - Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemiaBorje S Andersson
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Curr Opin Oncol 21:S11-5. 2009.... - Monitoring late-onset toxicities in phase I trials using predicted risksB Nebiyou Bekele
Department of Biostatistics, MD Anderson Cancer Center, Houston, TX 77030, USA
Biostatistics 9:442-57. 2008..This advantage increases with accrual rate, but the price of this additional safety is that the trial takes longer to complete on average... - Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancerArlene O Siefker-Radtke
Department of Genitourinary Medical Oncology, Urology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 27:2592-7. 2009..We now report results from the first phase II clinical trial developed exclusively for SCUC, to our knowledge... - Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson
Department of Stem Cell Transplantation and Cellular Therapy, U T M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030 4009, USA
Biol Blood Marrow Transplant 14:672-84. 2008..These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1... - A possible association between aprotinin and improved survival after radical surgery for mesotheliomaPeter H Norman
Department of Anesthesiology and Pain Medicine, Unit 409, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer 115:833-41. 2009..In this prospective, randomized, placebo-controlled, double-blind trial, the authors investigated whether aprotinin decreased blood loss in patients who underwent this operation... - Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemiaBorje S Andersson
Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77005, USA
Biol Blood Marrow Transplant 8:477-85. 2002..Given the ability of i.v. Bu to provide a more consistent per-dose AUC, these results should be useful in designing future i.v.V Bu-based treatment protocols for stem cell transplantation... - Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomasPeter W T Pisters
Multidisciplinary Sarcoma Center, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030 4009, USA
J Clin Oncol 22:3375-80. 2004.... - Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew
Department of Genitourinary Medical Oncology, Unit 427, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 22:3323-9. 2004..Our goals were to (1) evaluate the toxicity and maximum-tolerated dose of docetaxel with imatinib, and (2) evaluate the decline of prostate-specific antigen (PSA) induced by imatinib alone, and imatinib and docetaxel... - New designs for phase 2 clinical trialsElihu H Estey
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA
Blood 102:442-8. 2003..These concerns motivated the development of a general paradigm for randomized selection trials evaluating several therapies based on multiple outcomes. Three illustrative applications of trials using this approach are presented... - Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima
Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 104:857-64. 2004..The results suggest that intravenous busulfan-fludarabine is an efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS undergoing HSCT... - Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosideElihu H Estey
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 99:4343-9. 2002..Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome... - Simultaneously optimizing dose and schedule of a new cytotoxic agentThomas M Braun
Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
Clin Trials 4:113-24. 2007..Consequently, the overall risk of toxicity for each patient is a function of both actual schedule of treatment and the differing doses used at each adminstration... - Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding studyMarcos de Lima
Department of Stem Cell Transplantation and Cell Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 116:5420-31. 2010..The authors hypothesized that low-dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination... - Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II studyLance C Pagliaro
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 28:3851-7. 2010..We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy... - Bayesian adaptive model selection for optimizing group sequential clinical trialsJ Kyle Wathen
Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Box 447, 1515 Holcombe Boulevard, Houston, TX 77030, U S A
Stat Med 27:5586-604. 2008.... - Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignanciesPartow Kebriaei
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 17:412-20. 2011..Intravenous Bu-Mel was well tolerated. Disease control wa encouraging, and should be explored in larger phase II studies... - High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantationStefan O Ciurea
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Transplantation 88:1019-24. 2009..Anti-HLA sensitization should be evaluated routinely in hematopoietic stem-cell transplantation with HLA mismatched donors... - Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylateDejka M Steinert
Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Cancer 106:1617-23. 2006..Larger studies may help elucidate the influence of Bcl-2 expression on PFS after therapy with imatinib... - Monitoring the rates of composite events with censored data in phase II clinical trialsYing Kuen Cheung
Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
Biometrics 58:89-97. 2002..Application to a leukemia trial with a composite event shows that the method can reduce trial duration substantially while maintaining the reliability of interim decisions... - Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylateJohn C McAuliffe
Department of Sarcoma Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 13:6727-34. 2007..Importantly, selected patients may be treated with an approach to target both Kit and vascular endothelial growth factor receptor (VEGFR) expression... - Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantationRaymond Wong
Department of Blood and Marrow Transplantation, University of Texas M.D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Biol Blood Marrow Transplant 11:108-14. 2005.... - Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou
Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Natl Cancer Inst 101:306-20. 2009.... - A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancerStacy L Moulder
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301438, Houston, TX 77030, USA
Cancer 116:814-21. 2010..This study was performed to compare efficacy and toxicity profiles of paclitaxel using 3-hour versus 96-hour infusion schedules... - Durable remission with salvage second autotransplants in patients with multiple myelomaNina Shah
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer 118:3549-55. 2012..However, the role of salvage auto-HCT for relapsed patients, particularly in the era of novel therapeutics, is not well defined... - A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles
Department of Leukaemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Br J Haematol 121:578-85. 2003.... - A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosisJohn C McAuliffe
The University of Texas Houston, Houston, TX, USA
Ann Surg Oncol 16:910-9. 2009..02). Imatinib appears to be safe and may be considered for patients undergoing surgical resection of their GIST. Radiographic response and tumor cell apoptosis occur within the first week of imatinib therapy... - Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancersJon R Wiener
Department of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
Gynecol Oncol 88:73-9. 2003..The objective of this study was to determine if the Src tyrosine kinase is overexpressed and activated in late-stage human ovarian cancers... - Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri
Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
Clin Cancer Res 10:2968-76. 2004.... - Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]Robert G Maki
Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
J Clin Oncol 25:2755-63. 2007..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel... - Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefitBorje S Andersson
Biol Blood Marrow Transplant 9:722-4. 2003 - Some ethical issues in phase II trials in acute leukemiaPeter F Thall
Clin Adv Hematol Oncol 4:95. 2006 - Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in childrenHarry T Whelan
Division of Pediatric Neurology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA
Stroke 39:2627-36. 2008..This article describes a Bayesian outcome-adaptive method for determining the best dose of an experimental agent and explains how this method was used to design a dose-finding trial for tPA in childhood... - Determining the effective sample size of a parametric priorSatoshi Morita
Department of Epidemiology and Health Care Research, Kyoto University Graduate School of Medicine, Kyoto 606 8501, Japan
Biometrics 64:595-602. 2008..We provide general guidelines for application, illustrate the method in several standard cases where the answer seems obvious, and then apply it to some nonstandard settings... - Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34 cells in a closed liquid culture systemPeter H Shaw
Department of Pediatrics, University of Pittsburgh School of Medicine and Children s Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213 2583, USA
Biol Blood Marrow Transplant 9:151-6. 2003..Our ex vivo expansion technique needs to be further optimized before it can be used in a pilot UCB transplantation trial...
Research Grants
- STATISTICAL METHODS FOR COMPLEX CANCER TRIALSPeter F Thall; Fiscal Year: 2010....
- STATISTICAL METHODS FOR COMPLEX CANCER TRIALSPeter Thall; Fiscal Year: 2002..The aim is to provide a basis for safety monitoring in phase III trials that is part of the formal test, rather than an additional ad hoc procedure. ..
- STATISTICAL METHODS FOR COMPLEX CANCER TRIALSPeter Thall; Fiscal Year: 2006..In order to promulgate the methods to the statistical and medical communities, user-friendly computer software for implementation will be made freely available. ..